Skip to main content
Cellectar Biosciences, Inc. logo

Cellectar Biosciences, Inc. — Investor Relations & Filings

Ticker · CLRB ISIN · US15117F8077 LEI · 5493000NFZCRG7BYQV93 US Manufacturing
Open in API
Filings indexed 1,033 across all filing types
Latest filing 2013-03-14 Major Shareholding Noti…
Country US United States of America
Listing US CLRB

About Cellectar Biosciences, Inc.

https://www.cellectar.com/

Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted cancer treatments. The company's core technology is a proprietary Phospholipid Drug Conjugate (PDC) platform that selectively delivers therapeutic payloads, such as radioisotopes and cytotoxins, to cancer cells by targeting lipid rafts in their plasma membranes. This approach is designed to maximize antitumor activity while minimizing off-target effects on healthy tissue. Cellectar's lead product candidate is iopofosine I 131, a first-in-class PDC that delivers the radioisotope iodine-131. It is being developed for the treatment of hematologic malignancies and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for Waldenstrom's Macroglobulinemia.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2013
Major Shareholding Notification
2013-03-14 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 21, 2013, for Novelos Therapeutics, Inc. The key content is the announcement of the closing of a $5.5 million registered public offering of units consisting of common stock and warrants. The document includes a press release as an exhibit. The length is 2653 characters, which is relatively short and primarily serves as an announcement of a financing event rather than a detailed financial report. The main subject is a financing update, specifically a public offering closing. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2013-02-21 English
PROSPECTUS - RULE 424(B)(1)
Capital/Financing Update Classification · 100% confidence The document is a detailed prospectus for a securities offering by Novelos Therapeutics, Inc., specifically a Rule 424B1 prospectus related to an offering of units consisting of common stock and warrants. It includes detailed information about the offering, risk factors, use of proceeds, capitalization, management discussion and analysis, business overview, litigation, and financial statements. The presence of terms like 'prospectus', 'offering', 'units', 'shares', 'warrants', and detailed capital raising information clearly indicates this is a capital raising document. It is not an annual report, earnings release, or any other type of report but a financing document. Therefore, the correct classification is Capital/Financing Update (CAP). The document length (15,000 characters) and content confirm it is the full prospectus, not just an announcement or summary.
2013-02-15 English
RULE 424(B)(3)
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(3) under the Securities Act of 1933. It details the sale of units consisting of common stock and warrants, including pricing, terms, and proceeds from the offering. This type of document is related to capital raising activities and financing updates. It is not an annual or quarterly report, earnings release, or management discussion. It is specifically about a financing transaction and issuance of securities. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is a full filing of the financing update, not just an announcement or notice.
2013-02-15 English
RULE 424(B)(3)
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(3), which is a regulatory filing related to securities offerings. It details the sale of common stock and warrants, including the number of shares, pricing, and terms of the offering. The document does not contain financial statements or management discussion but focuses on capital raising activities. It is not an annual or quarterly report, earnings release, or management report. Given the content and the regulatory filing nature, this fits the category of Capital/Financing Update (CAP). The document length is relatively short and specific to a financing transaction, confirming the classification.
2013-02-14 English
FORM 8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated February 12, 2013, reporting the entry into a material definitive agreement related to a securities purchase agreement. It details the sale of common stock and warrants, the gross proceeds, placement agent fees, and includes exhibits such as the form of securities purchase agreement and warrants. The content focuses on a financing transaction and capital raising activity. There is no financial statement or earnings data presented, nor is it an announcement of a report publication or a regulatory certification. The primary subject is an update on the company's capital raising and financing activities, which fits the Capital/Financing Update category.
2013-02-14 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.